APPLICATION OF QUALITY BY DESIGN APPROACH FOR THE OPTIMIZATION OF ORODISPERSIBLE FILM FORMULATION
Keywords:Quality by design, Design of experiments, Critical quality attributes, Folding endurance, Naratriptan hydrochloride, Migraine
Objective: The present study was done to understand the effect of formulation variables on the quality of orodispersible films using quality by design (QbD) approach as mentioned in ICH Q8 (R2) guideline.
Methods: A definitive screening design of experiments (DoE) was used to identify and classify the critical formulation variables affecting critical quality attributes (CQA) using 2Ã—2 factorial design. Based on prescreening study, the critical formulation variables, i.e. concentration of film-forming polymer and plasticizers (propylene glycol and polyethylene glycol 400 [PEG 400]) were kept in the range of 1.5â€“2.5% w/w and 0.5â€“1% v/v, respectively. A total of eight laboratory-scale formulations were prepared which were provided by DoE using solvent casting method. These batches were evaluated for CQA's, i.e. mechanical properties such as folding endurance (FD) and disintegration time (DT). Data were analyzed for elucidating interactions between two variables and for providing a predictive model for the process. Finally, the drug was incorporated into optimized batches, and these were evaluated for in vitro dissolution study in simulated saliva (pH 6.8) as well as their mechanical properties.
Results: The results suggested that the concentration of film-forming polymer and plasticizer was critical to manufacture orodispersible film with desired CQA, i.e. mechanical property (FD [>150 folds]) and DT (<60 s). The percent drug release, FD, and DT of optimized Formulation I (hydroxypropyl methylcellulose [HPMC] E5 (2%) and propylene glycol [0.15 mL]) were found to be 82.13%Â±0.260 (in 15 min), 164Â±2, and 49Â±1.5 s, respectively, and for optimized Formulation II (HPMC E5 [2%] and PEG 400 [0.15 mL]) was found to be 64.26%Â±2.026 (in 15 min) and 218Â±6 and 55Â±4 s, respectively.
Conclusion: From the results, it has been found that the percentage drug release of naratriptan hydrochloride containing propylene glycol as a plasticizer was greater than the formulation containing PEG 400 as plasticizer. From this, we concluded that QbD is very much useful approach to get an optimized formulation in an economic and faster way in comparison to traditional method (hit and trail methods). The futuristic application of the film will involve the management of an acute migraine.
Steiner D, Finke JH, Kwade A. Redispersion of nanoparticle-loaded orodispersible films: Preservation of particle fineness. Chem Ing Tech 2017;89:1034-40.
Parmar D, Patel U, Bhimani B, Tripathi A, Daslaniya D, Patel G. Orally fast dissolving films as dominant dosage form for quick release. Int J Pharm Res BioSci 2012;1:27-41.
Visser JC, Woerdenbag HJ, Crediet S, Gerrits E, Lesschen MA, Hinrichs WL, et al. Orodispersible films in individualized pharmacotherapy: The development of a formulation for pharmacy preparations. Int J Pharm 2015;478:155-63.
Borges AF, Silva C, Coelho JF, SimÃµes S. Oral films: Current status and future perspectives: I - Galenical development and quality attributes. J Control Release 2015;206:1-19.
Priyanka P, Rikisha L, Mayur C, Ujjaval S. Development and optimization of fast dissolving or dispersible film of baclofen using 32 central composite designs. Int J Pharm Sci Res 2014;5:5539-47.
Arya A, Chandra A, Sharma V, Pathak K. Fast dissolving oral films: An innovative drug delivery system and dosage form. Int J Chem Technol Res 2010;2:576-83.
Mahaparale MA, Shivnikar SS, Pawar KV, Prashant N. Fast dissolving oral films: An innovative drug delivery system. Int J Res Rev Pharm Appl Sci 2012;2:482-96.
Sangshetti JN, Deshpande M, Zaheer Z, Shinde DB, Arote R. Quality by design approach: Regulatory need. Arabian J Chem 2017;10:3412-25.
Vecchia D, Pietrobon D. Migraine: A disorder of brain excitatory-inhibitory balance? Trends Neurosci 2012;35:507-20.
Goadsby PJ. Migraine: Diagnosis and management. Int Med J 2003;33:436-42.
Skaer TL. Clinical presentation and treatment of migraine. Clin Ther 1996;18:229-45.
Tepper SJ, Spears RC. Acute treatment of migraine. Neurol Clin 2009;27:417-27.
Estemalik E, Tepper S. Preventive treatment in migraine and the new US guidelines. Neuropsychiatr Dis Treat 2013;9:709-20.
Dhillon KS, Singh J, Lyall JS. A new horizon into the pathobiology, etiology and treatment of migraine. Med Hypotheses 2011;77:147-51.
Antonaci F, Natascia G, Shizheng W, Ennio P, Alfredo C. Recent advances in migraine therapy. Springerplus 2016;5:637.
Tayel SA, El Nabarawi MA, Amin MM, Abou Ghaly MH. Sumatriptan succinate sublingual fast dissolving thin films: Formulation and in vitro/in vivo evaluation. Pharm Dev Technol 2016;21:328-37.
Longmore J, Shaw D, Smith D, Hopkins R, McAllister G, Pickard JD, et al. Differential distribution of 5-HT1D and 5-HT1B-immunoreactivity within the human trigemino-cerebrovascular system: Implications for the discovery of new antimigraine drugs. Cephalalgia 1997;17:833-42.
Reuter U, Chiarugi A, Bolay H, Moskowitz MA. Nuclear factor-kappaB as a molecular target for migraine therapy. Ann Neurol 2003;51:507-16.
Chonkar AD, Rao JV, Managuli RS, Mutalik S, Dengale S, Jain P, et al. Development of fast dissolving oral films containing lercanidipine HCl nanoparticles in semi crystalline polymeric matrix for enhanced dissolution and ex vivo permeation. Eur J Pharm Biopharm 2016;103:179-91.
Sharma R, Kamboj S, Singh G, Rana V. Development of aprepitant loaded orally disintegrating films for enhanced pharmacokinetic performance. Eur J Pharm Sci 2016;84:55-69.
Mishra R, Amin A. Formulation and characterization of rapidly dissolving films of cetirizine hydrochloride using pullulan as a film forming agent. Indian J Pharm Educ Res 2011;45:71-7.
Saxena PR, De Vries P, VillalÃ³n CM. 5-HT1-like receptors: A time to bid goodbye. Trends Pharmacol Sci 1998;19:311-6.
How to Cite
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.